Inhibrx updates pipeline data as analysts rate Inhibrx stock Moderate Buy

Published on 10/05/2026 at 13:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx reported a USD 2.34 per-share loss in the second quarter versus USD 2.28 expected. Six brokers target Inhibrx stock at USD 197.50.

INBX, US45720N1037, Illustration mit AI erstellt.

Inhibrx Biosciences (ISIN US45720N1037) updated its corporate presentation on September 28, 2026, while six brokerages assigned Inhibrx stock a Moderate Buy consensus. The presentation update and the analyst split give investors two different signals: pipeline progress remains central, but valuation expectations vary widely.

Pipeline data gets a new update

According to SEC on September 28, 2026, Inhibrx posted an updated corporate presentation on its investor website. The filing describes the material as an investor update rather than a new financial report, making the pipeline information the main operating reference from the filing.

Inhibrx is a clinical-stage biotechnology company developing engineered biologic medicines for serious diseases with limited treatment options. Its platform is built around multifunctional proteins and antibody-based therapies, including candidates aimed at difficult-to-treat oncology indications.

Second-quarter loss missed estimates

In the second quarter of 2026, Inhibrx reported a net loss of USD 36.65 million and diluted earnings per share of USD -2.34. MarketBeat reported that the earnings-per-share result missed the USD -2.28 consensus estimate by USD 0.06.

The loss figure puts the pipeline update in financial context. Inhibrx is still funding development while revenue remained unreported for the quarter, so clinical milestones and cash use remain more important indicators than sales growth.

Analysts disagree on valuation

MarketBeat said on October 3, 2026, that six brokerages gave the company a Moderate Buy consensus and an average 12-month price target of USD 197.50. The ratings included one sell, two holds, two buys and one strong buy, showing a broad gap between confidence in the pipeline and caution over execution risk.

HC Wainwright began coverage with a Buy rating and a USD 245.00 target on August 24, 2026, while Citigroup later maintained a Market Perform view on September 18, 2026, according to MarketBeat.

Nasdaq range sets the frame

On Nasdaq, Inhibrx was at USD 96.99 at the close on October 2, 2026. The 52-week range was USD 28.16 to USD 155.29, while market capitalization stood at USD 1.4 billion on that date. These figures place the average analyst target well above the latest completed Nasdaq session, but the earnings miss and clinical execution remain material factors.